Author/Authors :
Balijepalli, Chakrapani Faculty of Health Sciences - Simon Fraser University - Burnaby - BC, Canada , Druyts, Eric Faculty of Medicine - University of British Columbia - Vancouver - BC, Canada , Yan, Kevin Faculty of Medicine - University of British Columbia - Vancouver - BC, Canada , Zoratti, Michael J. Department of Clinical Epidemiology and Biostatistics - McMaster University - Hamilton - ON, Canada , Thorlund , Kristian Department of Clinical Epidemiology and Biostatistics - McMaster University - Hamilton - ON, Canada , Wu, Ping Canadian College of Naturopathic Medicine - Toronto - ON, Canada , Kanji, Salmaan Department of Pharmacy - The Ottawa Hospital and Ottawa Hospital Research Institute - Ottawa - ON, Canada , Rabheru, Kiran DepartmentofPsychiatry - OttawaHospital - Ottawa - ON, Canada
Abstract :
reatment of schizophrenia with first- and second-generation antipsychotics has been associated with elevatedprolactin levels, which may increase the risk for prolactin-related adverse events.Methods. Randomized controlled trials (RCTs)included in a recent systematic review were considered for this analysis. A Bayesian network meta-analysis was used to comparechanges in prolactin levels in pediatric patients diagnosed with schizophrenia or schizophrenia spectrum disorders treated withsecond-generation antipsychotics (SGAs).Results. Five RCTs, including 989 patients combined, have evaluated the changes inprolactin for pediatric patients after 6 weeks of treatment with risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone. Inthe overall study population, treatment with risperidone was associated with the highest increase in mean prolactin levels comparedto other SGAs. Patients treated with risperidone 4–6 mg/day were found to experience the greatest increases (55.06 ng/ml [95%CrI: 40.53–69.58]) in prolactin levels, followed by risperidone 1–3 mg/day, paliperidone 3–6 mg/day, and paliperidone 6–12 mg/day.Conclusions. This study shows that there are differences in SGAs ability to cause hyperprolactinemia. Further, there is clear evidenceof safety concerns with risperidone and paliperidone treatment in adolescent schizophrenia patients.Registration.PROSPEROCRD42014009506
Keywords :
Change in Prolactin Levels , Pediatric Patients Given Antipsychotics , Schizophrenia , Schizophrenia Spectrum Disorders , A Network Meta-Analysis
